Gastroenteropancreatic Neuroendocrine Tumor Clinical Trial
Official title:
Pilot Phase 1 Study of Perioperative Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic, WHO Grade 1 or 2, SSTR Positive, Gastroenteropancreatic Neuroendocrine Tumors Who Are Candidates for Cytoreductive Surgery
The purpose of this study is to learn about the feasibility and safety of using Peptide Receptor Radionuclide Therapy (PRRT) before and after surgical removal of a tumor. PRRT treatment is based on the administration of a radioactive product, 177-Lu DOTA-0-Tyr3-Octreotate (Lutathera®) and its use before and after surgery is thought to increase the overall survival benefit for patients with SSTR-positive gastroenteropancreatic neuroendocrine tumors GEP-NETs.
Status | Recruiting |
Enrollment | 10 |
Est. completion date | September 2027 |
Est. primary completion date | March 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Metastatic gastroenteropancreatic NET with lymph nodes or liver metastases only. 2. WHO Grade 1 or 2, Ki 67 = 20% (to be confirmed at Stanford) 3. Must be a candidate for cytoreductive surgery with the goal of R1 resection as determined by a multidisciplinary tumor board discussion 4. Measurable disease as determined by RECIST v1.1 5. Confirmed presence of somatostatin receptors on all target lesions as determined by 68Ga DOTA TATE PET scan 6. Patients = 18 years of age. 7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 1 8. Appropriate hematologic, liver and kidney function 9. Patients on octreotide long-acting release (LAR) at a fixed dose of 20 mg or 30 mg at 3 to 4 weeks intervals for at least 12 weeks prior to enrollment in the study Exclusion Criteria: 1. Prior 177Lu Dotatate treatment 2. Any surgery or radiofrequency ablation within 12 weeks prior to enrollment in the study; or prior radioembolization; chemoembolization; or external beam radiation therapy (EBRT) to > 25% of bone marrow, at any time 3. Any chemotherapy or targeted therapy (including everolimus and sunitinib) within 4 weeks prior to enrollment in the study 4. Known brain metastases 5. Known bone or peritoneal metastases |
Country | Name | City | State |
---|---|---|---|
United States | Stanford Cancer Institute Palo Alto | Stanford | California |
Lead Sponsor | Collaborator |
---|---|
Stanford University | Novartis Pharmaceuticals |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measure Complication free Surgery | The feasibility of perioperative 177Lu Dotatate as part of the therapeutic regimen to treat metastatic neuroendocrine tumors (NETs) will be assessed on the basis of number and proportion of participants who undergo 2 cycles of complication free 177Lu Dotatate therapy followed by cytoreductive surgery without complications, expressed as a number without dispersion. Complications are defined as follows.
Radiation fibrosis Hepatic fibrosis by histologic diagnosis Hepatic insufficiency Bowel anastamotic leak (if bowel surgery) Distal pancreatic leak (if pancreas surgery) |
6 months | |
Secondary | Response Rate (RR) | Response Rate (RR), as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria, will be determined after 2 pre operative cycles of 177Lu Dotatate. RR will be assessed as the sum of complete response (CR) and partial response (PR), and expressed as a number without dispersion. RECIST criteria are:
CR = Disappearance of all target lesions PR = = 30% decrease in the sum of the longest diameter of target lesions Response Rate (RR) = CR + PR Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions, and/or the appearance of one or more new lesion(s) Stable disease (SD) = Small changes that do not meet any of the above criteria |
16 weeks | |
Secondary | Recurrence free Survival (RFS) | Recurrence free Survival (RFS) is defined as the number and proportion of participants that remain alive from the start of treatment without relapse or recurrence of disease, expressed as a number without dispersion. | 1 year | |
Secondary | Overall Survival (OS) | Overall survival (OS) is defined as the number and proportion of participants that remain alive from the start of treatment, expressed as a number without dispersion. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06155318 -
68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours
|
||
Terminated |
NCT01994213 -
A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
|
Phase 2 | |
Active, not recruiting |
NCT03980925 -
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
|
Phase 2 | |
Recruiting |
NCT02611024 -
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT04852679 -
Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
|
Phase 3 | |
Enrolling by invitation |
NCT05064150 -
Neuroendocrine Tumors - Patient Reported Outcomes
|
||
Active, not recruiting |
NCT04727723 -
Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
|
||
Recruiting |
NCT06256705 -
Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort
|
N/A | |
Active, not recruiting |
NCT05477576 -
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
|
Phase 3 | |
Recruiting |
NCT05701241 -
Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients
|
Phase 4 | |
Completed |
NCT02948946 -
Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
|
||
Withdrawn |
NCT04915144 -
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
|
Phase 2 | |
Recruiting |
NCT04986085 -
Nutrition in Gastroenteropancreatic Neuroendocrine Tumor
|
||
Active, not recruiting |
NCT05262556 -
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
|
Phase 1 | |
Completed |
NCT03017690 -
Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
|